Subscribe to the BioNews newsletter for free

Advanced Search

Search for

Like the Progress Educational Trust on Facebook



Chemotherapy during pregnancy could affect daughters' fertility

15 August 2016

By Dr Nicoletta Charolidi

Appeared in BioNews 864

A study has shown that the chemotherapy drug etoposide can affect the development of fetal ovarian tissue in mice. The findings suggest that chemotherapy treatment given to pregnant women with cancer during their second trimester could reduce the future fertility of baby girls.

Researchers at the University of Edinburgh studied the effects of etoposide on lab-grown ovarian tissue from mouse fetuses, both before and after follicle formation. They showed that exposure of the tissue to medium to high doses of this drug before the follicles had formed could reduce follicle formation by up to 90 percent.

However, exposure to the same amounts or higher concentrations of etoposide after the formation of follicles in neonatal mouse ovaries had no effect, suggesting that the timing of the treatment could be a crucial factor in how it may affect future fertility.

Lead author, Professor Norah Spears, from the Centre for Integrative Physiology, said: 'If the results we have seen in these mouse studies are replicated in human tissue, it could mean that girls born to mums who are taking etoposide during pregnancy have a reduced fertility window.' Follicles are responsible for producing eggs, and a lower follicle count can result in women undergoing the menopause earlier than usual.

One in a thousand pregnant women is diagnosed with cancer. Etoposide is routinely used by the NHS to treat several types of cancer during the second and third trimester of pregnancy because of its low risk of causing birth defects and spontaneous abortion. However, the longer term effects for fetuses have not yet been fully explored.

Women acquire their reproductive capacity before birth, during the second and third trimester of their mothers' pregnancy. Specialised cells, called primordial germ cells, drive formation of all their eggs, which are then stored in the developing fetal ovaries from that point on. This study suggests that etoposide can harm these germs cells and the developing follicles.

Professor Adam Balen, chairman of the British Fertility Society and a representative of the Royal College of Obstetricians and Gynaecologists, said that 'while this is important information for pregnant women who may need chemotherapy, it is too early to say the degree to which this study carried out in mice might relate to humans'.

The researchers say that if the findings are verified in women, affected baby girls should be warned of their reduced fertility in later life and offered fertility options. However, these risks should be also weighed against the benefits of taking etoposide, Professor Balen added.

'We must also weigh any benefits of cancer treatment against these potential risks. These decisions should be made jointly between a woman and her specialist healthcare team,' he said.


10 July 2017 - by Mikey Lebrett 
Female cancer survivors are 38 per cent less likely to become pregnant compared with women in the general population, according to a study presented at the annual European Society of Human Reproduction and Embryology conference in Geneva...
24 October 2016 - by Annabel Slater 
Artificial sweeteners found in soft drinks may reduce female fertility, a study suggests...

01 February 2016 - by Fiona Ibanichuka 
Scientists have discovered that the use of painkillers during pregnancy in rats may reduce the fertility of their offspring...
12 October 2015 - by Dr Rachel Brown 
A Danish study has reported that ovarian tissue transplants appear to be safe and can restore fertility in women who have undergone treatment for cancer, with around one in three procedures in young women leading to live births....
20 July 2015 - by Ceri Durham 
Abnormal results from a non-invasive prenatal test for fetal chromosome abnormality may indicate the presence of previously undetected cancers in some mothers....
09 March 2015 - by Kirsty Oswald 
US company Sequenom has revealed that its prenatal blood test - MaterniT21 PLUS - has detected potential cancer in at least 40 expectant mothers since its launch three years ago...

Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

- click here to enquire about using this story.

Published by the Progress Educational Trust


Public Conference
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation